In vivo imaging system (IVIS) therapeutic assessment of tyrosine kinase inhibitor-loaded gold nanocarriers for acute myeloid leukemia: a pilot study

• Egile Nagusiak: Raluca-Andrada Munteanu (Egilea), Adrian Bogdan Tigu (Egilea), Richard Feder (Egilea), Andra-Sorina Tatar (Egilea), Diana Gulei (Egilea), Ciprian Tomuleasa (Egilea), Sanda Boca (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Acute myeloid leukemia (AML) is a malignancy in the myeloid lineage that is characterized by symptoms like fatigue, bleeding, infections, or anemia, and it can be fatal if untreated. In AML, mutations in tyrosine kinases (TKs) lead to enhanced tumor cell survival. The most frequent mutations in TKs...